Seres Therapeutics Q2 2024 GAAP EPS $(0.22) Beats $(0.27) Estimate, $71.2M In Cash And Cash Equivalents That Is Expected To Fund Operations Into The Fourth Quarter Of 2025
Portfolio Pulse from Benzinga Newsdesk
Seres Therapeutics reported a Q2 2024 GAAP EPS of $(0.22), beating the estimate of $(0.27). The company has $71.2 million in cash and cash equivalents, expected to fund operations into Q4 2025.

August 13, 2024 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Seres Therapeutics reported a better-than-expected Q2 2024 GAAP EPS of $(0.22) compared to the estimated $(0.27). The company also has $71.2 million in cash and cash equivalents, which is expected to fund operations into the fourth quarter of 2025.
The better-than-expected EPS indicates stronger financial performance, which is likely to positively impact the stock price in the short term. Additionally, the substantial cash reserves provide a solid financial foundation, reducing liquidity concerns.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100